Ayalew Tefferi – författare

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeutics. Written in an easy-to-follow text myeloproliferative disorders gives the practicing clinician a single source answer to classification, diagnosis, management, and recent advances in this disorder.

Ayalew Tefferi, MD, and a team of authoritative practicing physicians concisely detail their most effective approaches to the diagnosis and treatment of a wide variety of hematological disorders, including anemia and other cytopenias, primary and secondary myeloproliferative disorders, lymphoid and plasma cell disorders, and thrombotic and bleeding disorders. For each illness these expert clinicians provide a brief review of basic concepts and a discussion of its symptomology and classification, its diagnostic tests, and strategies for its management, along with suggested readings for more detailed information. Numerous decision trees clarify diagnosis, and summary boxes highlight key points and dosage parameters. Concise, practical, and up-to-date, Primary Hematology offers busy primary care physicians, internists, hematologists, and oncologists a much-needed action-oriented summary of proven approaches to the optimal diagnosis and treatment of hematologic disorders today.

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeuti

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeuti

Ayalew Tefferi, MD, and a team of authoritative practicing physicians concisely detail their most effective approaches to the diagnosis and treatment of a wide variety of hematological disorders, including anemia and other cytopenias, primary and secondary myeloproliferative disorders, lymphoid and plasma cell disorders, and thrombotic and bleeding disorders. For each illness these expert clinicians provide a brief review of basic concepts and a discussion of its symptomology and classification, its diagnostic tests, and strategies for its management, along with suggested readings for more detailed information. Numerous decision trees clarify diagnosis, and summary boxes highlight key points and dosage parameters. Concise, practical, and up-to-date, Primary Hematology offers busy primary care physicians, internists, hematologists, and oncologists a much-needed action-oriented summary of proven approaches to the optimal diagnosis and treatment of hematologic disorders today.

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

Ayalew Tefferi, MD, and a team of authoritative practicing physicians concisely detail their most effective approaches to the diagnosis and treatment of a wide variety of hematological disorders, including anemia and other cytopenias, primary and secondary myeloproliferative disorders, lymphoid and plasma cell disorders, and thrombotic and bleeding disorders. For each illness these expert clinicians provide a brief review of basic concepts and a discussion of its symptomology and classification, its diagnostic tests, and strategies for its management, along with suggested readings for more detailed information. Numerous decision trees clarify diagnosis, and summary boxes highlight key points and dosage parameters. Concise, practical, and up-to-date, Primary Hematology offers busy primary care physicians, internists, hematologists, and oncologists a much-needed action-oriented summary of proven approaches to the optimal diagnosis and treatment of hematologic disorders today.

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.